MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 527676 | Name: Piperacetazine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Piperacetazine is an antipsychotic prodrug, most notably used for schizophrenia. Piperacetazine inhibits the transcriptional activity of the PAX3::FOXO1 fusion protein. Piperacetazine was amonga group of drugs studied for its ability to be repurposed into exhibiting anti-SARS-CoV-2 activity.

Chemical Structure

Piperacetazine
Piperacetazine
CAS#3819-00-9

Theoretical Analysis

MedKoo Cat#: 527676

Name: Piperacetazine

CAS#: 3819-00-9

Chemical Formula: C24H30N2O2S

Exact Mass: 410.2028

Molecular Weight: 410.58

Elemental Analysis: C, 70.21; H, 7.37; N, 6.82; O, 7.79; S, 7.81

Price and Availability

Size Price Availability Quantity
10mg USD 380.00 2 Weeks
50mg USD 700.00 2 Weeks
100mg USD 975.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Piperacetazine
IUPAC/Chemical Name
1-[10-[3-[4-(2-Hydroxyethyl)piperidin-1-yl]propyl]phenothiazin-2-yl]ethanone
InChi Key
BTFMCMVEUCGQDX-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H30N2O2S/c1-18(28)20-7-8-24-22(17-20)26(21-5-2-3-6-23(21)29-24)13-4-12-25-14-9-19(10-15-25)11-16-27/h2-3,5-8,17,19,27H,4,9-16H2,1H3
SMILES Code
CC(C(C=C1N2CCCN3CCC(CCO)CC3)=CC=C1SC4=C2C=CC=C4)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 410.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Nakazawa K, Shaw T, Song YK, Kouassi-Brou M, Molotkova A, Tiwari PB, Chou HC, Wen X, Wei JS, Deniz E, Toretsky JA, Keller C, Barr FG, Khan J, Üren A. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity. Cancer Res Commun. 2023 Oct 6;3(10):2030-2043. doi: 10.1158/2767-9764.CRC-23-0119. PMID: 37732905; PMCID: PMC10557868. 2: Deng J, Zhang Q, Lv L, Ma P, Zhang Y, Zhao N, Zhang Y. Identification of an autophagy-related gene signature for predicting prognosis and immune activity in pancreatic adenocarcinoma. Sci Rep. 2022 Apr 29;12(1):7006. doi: 10.1038/s41598-022-11050-w. PMID: 35488119; PMCID: PMC9054801. 3: Chen CZ, Shinn P, Itkin Z, Eastman RT, Bostwick R, Rasmussen L, Huang R, Shen M, Hu X, Wilson KM, Brooks BM, Guo H, Zhao T, Klump-Thomas C, Simeonov A, Michael SG, Lo DC, Hall MD, Zheng W. Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2. Front Pharmacol. 2021 Jan 25;11:592737. doi: 10.3389/fphar.2020.592737. PMID: 33708112; PMCID: PMC7942396. 4: Chen CZ, Shinn P, Itkin Z, Eastman RT, Bostwick R, Rasmussen L, Huang R, Shen M, Hu X, Wilson KM, Brooks B, Guo H, Zhao T, Klump-Thomas C, Simeonov A, Michael SG, Lo DC, Hall MD, Zheng W. Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2. bioRxiv [Preprint]. 2020 Aug 18:2020.08.18.255877. doi: 10.1101/2020.08.18.255877. Update in: Front Pharmacol. 2021 Jan 25;11:592737. doi: 10.3389/fphar.2020.592737. PMID: 32839771; PMCID: PMC7444282. 5: Eslami Shahrbabaki M, Dehnavieh R, Vali L, Sharafkhani R. Chlorpromazine versus piperacetazine for schizophrenia. Cochrane Database Syst Rev. 2018 Oct 31;10(10):CD011709. doi: 10.1002/14651858.CD011709.pub2. PMID: 30378678; PMCID: PMC6517193. 6: Dyall J, Nelson EA, DeWald LE, Guha R, Hart BJ, Zhou H, Postnikova E, Logue J, Vargas WM, Gross R, Michelotti J, Deiuliis N, Bennett RS, Crozier I, Holbrook MR, Morris PJ, Klumpp-Thomas C, McKnight C, Mierzwa T, Shinn P, Glass PJ, Johansen LM, Jahrling PB, Hensley LE, Olinger GG Jr, Thomas C, White JM. Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures. J Infect Dis. 2018 Nov 22;218(suppl_5):S672-S678. doi: 10.1093/infdis/jiy304. PMID: 29939303; PMCID: PMC6249579. 7: Dominguez RA. Tardive dyskinesia following low doses of piperacetazine. Am J Psychiatry. 1980 Dec;137(12):1617. doi: 10.1176/ajp.137.12.1617. PMID: 6108083. 8: Mandelker L. Clinical use of piperacetazine to modify behavior in dogs and cats: a practitioner's viewpoint. Vet Med Small Anim Clin. 1979 Apr;74(4):505-9. PMID: 36711. 9: Amin MM, Brahm E, Ban TA, Lehmann HE. An uncontrolled clinical study with piperacetazine in the maintenance treatment of chronic schizophrenic patients. Psychopharmacol Bull. 1977 Jul;13(3):10-1. PMID: 18753. 10: Goldstein SE, Birnbom F. Piperacetazine versus thioridazine in the treatment of organic brain disease: a controlled double-blind study. J Am Geriatr Soc. 1976 Aug;24(8):355-8. doi: 10.1111/j.1532-5415.1976.tb03311.x. PMID: 7588. 11: Lapierre YD, Lee M. Piperacetazine in the treatment of mixed neurotics. Curr Ther Res Clin Exp. 1976 Jan;19(1):105-9. PMID: 1209. 12: Galambos M. Letter: Energizing effects of piperacetazine. Am J Psychiatry. 1975 Dec;132(12):1333-4. doi: 10.1176/ajp.132.12.aj132121333. PMID: 917. 13: del Portillo L. Piperacetazine study in state hospital patients. J Med Assoc Ga. 1974 Dec;63(12):465-7. PMID: 4154960. 14: Yeung KY, Corn M. Letter: Fatal aplastic anemia with piperacetazine therapy. Ann Intern Med. 1974 Sep;81(3):411. doi: 10.7326/0003-4819-81-3-411. PMID: 4152939. 15: Jeffries JJ. Letter: Piperacetazine-induced failure to ejaculate. Can Psychiatr Assoc J. 1974 Jun;19(3):322-3. doi: 10.1177/070674377401900322. PMID: 4152178. 16: Scott DW. Clinical use of piperacetazine in dogs and cats. Vet Med Small Anim Clin. 1974 Jun;69(6):723 p. PMID: 4151700. 17: Ananth J, Kulkarni AS. Letter: Side effects of chlorpromazine and piperacetazine. Am J Psychiatry. 1974 Jun;131(6):722. doi: 10.1176/ajp.131.6.722. PMID: 4151260. 18: Donlon PT, Rada RT. High dosage piperacetazine (Quide) in ambulatory schizophrenic patients--therapeutic efficacy and toxicity. Dis Nerv Syst. 1974 May;35(5):231-6. PMID: 17894106. 19: Rada RT, Donlon PT. Piperacetazine in ambulatory chronic schizophrenic patients. Curr Ther Res Clin Exp. 1974 Feb;16(2):124-9. PMID: 4156665. 20: Kulkarni AS. Clinical effectiveness of piperacetazine injection in schizophrenic patients: a controlled study. Adv Biochem Psychopharmacol. 1974;9(0):691-9. PMID: 4151770.